secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001104659-23-121738
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics extends Adcirca license with Lilly through Dec 2026
-----------------------------------------------------------------------

- Exclusive US marketing license for Adcirca extended from Dec 31, 2023 to Dec 31, 2026.
- Other terms of the license agreement remain unchanged.
- Adcirca (tadalafil) is for treatment of pulmonary hypertension in the US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465923121738/0001104659-23-121738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465923121738/tm2323177d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-121738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer